Firms

JLS Fund

JLS Fund

jls.fund

New York venture capital firm founded in 2019 that finances and helps build companies translating neuroscience, technology and data into treatments and services for patients. Its precision neuromedicine focus includes neuropsychiatric therapeutics, psychedelic medicine, mental-health care and enabling technologies. JLS backs drug developers and companies providing tools or infrastructure for neurological and psychiatric care, and supports their growth and strategic partnerships through its investment team and scientific, clinical and policy advisers.

Founded
2019
Type
Venture capital

Funds1

  • JLS Fund II LP$13M

    Venture capital pooled investment vehicle in JLS Fund’s neuroscience and precision neuromedicine strategy. Its May 11, 2026 SEC Form D amendment reports $13,029,190 of fund interests sold to 41 investors, an indefinite total offering and a first sale on December 18, 2023. The amount is cumulative reported sold capital at the filing date, not an announced final close or target. The Delaware partnership was formed in 2023; its general partner is JLS Fund II GP LLC, whose managing members include Lindsay Hoover and Simeon Schnapper.

Team

David Hirsch
—— – —

Operations and support

Andrew TatarskyAdvisor
Brendan HusseyPrincipal
Ethan NadelmannAdvisor
Gul DolenAdvisor
Jeffrey SiegelPartner & Investor Relations
Leonard PickardAdvisor
Lindsay HooverManaging Partner
Mark LoshAdvisor
Nick GillespieAdvisor
Simeon SchnapperManaging Partner
Walter GreenleafWalter GreenleafAdvisor

Co-investing

LifeSpan Vision Ventures
Remiges Ventures

Investments